Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails
17/06/2024 13:51
June 17 (Reuters) - Aerovate Therapeutics AVTE.O said on Monday it is shutting down the late-stage portion of a study testing its experimental hypertension drug after failing to meet the main goal in a mid-stage trial. (Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri) ((Pratik.Jain@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million